260 related articles for article (PubMed ID: 30365877)
1. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.
Cunningham KP; Holden RG; Escribano-Subias PM; Cogolludo A; Veale EL; Mathie A
J Physiol; 2019 Feb; 597(4):1087-1101. PubMed ID: 30365877
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Heterozygous
Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
[TBL] [Abstract][Full Text] [Related]
3. Characterization of
Lambert M; Capuano V; Boet A; Tesson L; Bertero T; Nakhleh MK; Remy S; Anegon I; Pechoux C; Hautefort A; Rucker-Martin C; Manoury B; Domergue V; Mercier O; Girerd B; Montani D; Perros F; Humbert M; Antigny F
Circ Res; 2019 Sep; 125(7):678-695. PubMed ID: 31347976
[TBL] [Abstract][Full Text] [Related]
4. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
5. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
[TBL] [Abstract][Full Text] [Related]
6. KCNK3: new gene target for pulmonary hypertension?
Girerd B; Perros F; Antigny F; Humbert M; Montani D
Expert Rev Respir Med; 2014 Aug; 8(4):385-7. PubMed ID: 24742047
[TBL] [Abstract][Full Text] [Related]
7. Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload.
Lambert M; Mendes-Ferreira P; Ghigna MR; LeRibeuz H; Adão R; Boet A; Capuano V; Rucker-Martin C; Brás-Silva C; Quarck R; Domergue V; Vachiéry JL; Humbert M; Perros F; Montani D; Antigny F
Cardiovasc Res; 2021 Nov; 117(12):2474-2488. PubMed ID: 33483721
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
[TBL] [Abstract][Full Text] [Related]
9. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
[TBL] [Abstract][Full Text] [Related]
10. A novel channelopathy in pulmonary arterial hypertension.
Ma L; Roman-Campos D; Austin ED; Eyries M; Sampson KS; Soubrier F; Germain M; Trégouët DA; Borczuk A; Rosenzweig EB; Girerd B; Montani D; Humbert M; Loyd JE; Kass RS; Chung WK
N Engl J Med; 2013 Jul; 369(4):351-361. PubMed ID: 23883380
[TBL] [Abstract][Full Text] [Related]
11. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
[TBL] [Abstract][Full Text] [Related]
12. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
[TBL] [Abstract][Full Text] [Related]
13. KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.
West JD; Austin ED; Rizzi EM; Yan L; Tanjore H; Crabtree AL; Moore CS; Muthian G; Carrier EJ; Jacobson DA; Hamid R; Kendall PL; Majka S; Rathinasabapathy A
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065088
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
[TBL] [Abstract][Full Text] [Related]
15. Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells.
Le Ribeuz H; Dumont F; Ruellou G; Lambert M; Balliau T; Quatredeniers M; Girerd B; Cohen-Kaminsky S; Mercier O; Yen-Nicolaÿ S; Humbert M; Montani D; Capuano V; Antigny F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036472
[TBL] [Abstract][Full Text] [Related]
16. Functional interaction of the two-pore domain potassium channel TASK-1 and caveolin-3.
Kang C; Hernandez VA; Hu K
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1537-1544. PubMed ID: 28648645
[TBL] [Abstract][Full Text] [Related]
17. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation.
Seyler C; Duthil-Straub E; Zitron E; Gierten J; Scholz EP; Fink RH; Karle CA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2012 Mar; 165(5):1467-75. PubMed ID: 21838752
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives.
Boutou AK; Pitsiou G
Expert Opin Pharmacother; 2020 Jul; 21(10):1145-1155. PubMed ID: 32089012
[TBL] [Abstract][Full Text] [Related]
19. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
20. The genetic basis of pulmonary arterial hypertension.
Ma L; Chung WK
Hum Genet; 2014 May; 133(5):471-9. PubMed ID: 24442418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
